Patrick Mehlen is director of the “Laboratoire d’Excellence” DEVweCAN, deputy-director of the Research Cancer Center of Lyon, co-director of the translational department in Léon Bérard Comprehensive Cancer Center in Lyon, France and co-founder & CEO of NETRIS Pharma. He is Adjunct Professor at the Buck Institute for Age Research, California. He has published over 150 peer-reviewed scientific publications and has received several awards including the silver medal from CNRS and the Pius XI Gold Medal from Pontificia Academia Scientiarum. Prof. Mehlen was elected EMBO member in 2006 and member of the French Academy of Sciences in 2013.



Agnès Bernet is Professor of cancer biology at the University Claude Bernard Lyon I. Co-founder of NETRIS Pharma, she led within the Laboratory of Apoptosis, Cancer and Development, the research team that validated the use of interference ligand/dependence receptors as novel targeted therapies for oncology. Agnès Bernet was nominated to the “Institut Universitaire de France”, which recognizes the best French academic researchers and has followed a course of entrepreneurship at the Lyon Management School and at Boston Babson College (USA).



Stéphane Depil has significant expertise in conducting pre-clinical and clinical development in oncology as the former head of Oncology R&D at Servier. Consulting physician in Institut Gustave Roussy, Villejuif, France, from 2007 to 2014, Dr Stéphane Depil is also onco-hematologist at Léon Bérard Cancer Center and Adjunct Professor at University Claude Bernard Lyon I.
He received his medical degree and a specialized postgraduate degree in hematology in 2002 from Lille Medical School, France. He obtained his Ph.D. in immunology in 2005 from Lille University and also received several postgraduate diplomas from Lille University and University of Paris VII.



Jordan Guyon is responsible for all elements of NETRIS Pharma operational management and acts as the financial controller. He received his Doctor of Pharmacy degree from the Faculty of Pharmacy of Lyon and then studied entrepreneurship at EM Lyon Business School. Before joining NETRIS Pharma, Jordan Guyon worked on business modeling and economic valuation at Merck KGaA.



Farid Bouzidi has extensive experience in partnering, business development, product development and launch. He possesses strong R&D background with pharmaceutical & biotechnological education spanning from pharmaceutical sciences to viral and diagnostics biotechnology. Throughout his career at companies such as Genentech, Pasteur, Theradiag, AC Immune, he gained a proven track record in business and corporate development across a range of clinical indications. With an abundance of international experience, Farid has a strong understanding of various markets throughout North America, Europe, Asia, and the Middle East. Farid obtained his Ph.D. in Biophysics and Biochemistry in Immunology from the French Atomic Agency and Joseph Fourier University in Grenoble, France. He holds an MBA from EM-Lyon, France and is board certified in critical reading and interpretation of clinical trials for the medical practice from Lyon School of Medicine.



Christophe Guichard has been managing corporate finance activities in strong growth environments since 1994, first within KPMG/Salustro and then as CFO of Trader Classified Media, performing major Equity and Debt M&A transactions including two IPOs (Nasdaq / Euronext and LSE). Christophe is a graduate from EDHEC Business School and Harvard Business School (PLD) and holds a postgraduate degree in accounting and Finance (DESCF).